Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
BioTech Gate,
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study Mechanisms of Action May Address…